WHISTLE: a high-accuracy map of the human N6-methyladenosine (m6A) epitranscriptome predicted using a machine learning approach
- PMID: 30993345
- PMCID: PMC6468314
- DOI: 10.1093/nar/gkz074
WHISTLE: a high-accuracy map of the human N6-methyladenosine (m6A) epitranscriptome predicted using a machine learning approach
Abstract
N 6-methyladenosine (m6A) is the most prevalent post-transcriptional modification in eukaryotes, and plays a pivotal role in various biological processes, such as splicing, RNA degradation and RNA-protein interaction. We report here a prediction framework WHISTLE for transcriptome-wide m6A RNA-methylation site prediction. When tested on six independent datasets, our approach, which integrated 35 additional genomic features besides the conventional sequence features, achieved a major improvement in the accuracy of m6A site prediction (average AUC: 0.948 and 0.880 under the full transcript or mature messenger RNA models, respectively) compared to the state-of-the-art computational approaches MethyRNA (AUC: 0.790 and 0.732) and SRAMP (AUC: 0.761 and 0.706). It also out-performed the existing epitranscriptome databases MeT-DB (AUC: 0.798 and 0.744) and RMBase (AUC: 0.786 and 0.736), which were built upon hundreds of epitranscriptome high-throughput sequencing samples. To probe the putative biological processes impacted by changes in an individual m6A site, a network-based approach was implemented according to the 'guilt-by-association' principle by integrating RNA methylation profiles, gene expression profiles and protein-protein interaction data. Finally, the WHISTLE web server was built to facilitate the query of our high-accuracy map of the human m6A epitranscriptome, and the server is freely available at: www.xjtlu.edu.cn/biologicalsciences/whistle and http://whistle-epitranscriptome.com.
© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.
Figures


Similar articles
-
WHISTLE: A Functionally Annotated High-Accuracy Map of Human m6A Epitranscriptome.Methods Mol Biol. 2021;2284:519-529. doi: 10.1007/978-1-0716-1307-8_28. Methods Mol Biol. 2021. PMID: 33835461
-
m6A-Atlas: a comprehensive knowledgebase for unraveling the N6-methyladenosine (m6A) epitranscriptome.Nucleic Acids Res. 2021 Jan 8;49(D1):D134-D143. doi: 10.1093/nar/gkaa692. Nucleic Acids Res. 2021. PMID: 32821938 Free PMC article.
-
WHISTLE server: A high-accuracy genomic coordinate-based machine learning platform for RNA modification prediction.Methods. 2022 Jul;203:378-382. doi: 10.1016/j.ymeth.2021.07.003. Epub 2021 Jul 7. Methods. 2022. PMID: 34245870
-
Cracking the epitranscriptome.RNA. 2016 Feb;22(2):169-74. doi: 10.1261/rna.054502.115. RNA. 2016. PMID: 26787305 Free PMC article. Review.
-
The role of N6-methyladenosine (m6A) in eye diseases.Mol Biol Rep. 2021 Aug;48(8):6145-6150. doi: 10.1007/s11033-021-06596-3. Epub 2021 Jul 31. Mol Biol Rep. 2021. PMID: 34331665 Review.
Cited by
-
RNADSN: Transfer-Learning 5-Methyluridine (m5U) Modification on mRNAs from Common Features of tRNA.Int J Mol Sci. 2022 Nov 4;23(21):13493. doi: 10.3390/ijms232113493. Int J Mol Sci. 2022. PMID: 36362279 Free PMC article.
-
Identification and Validation of a m5C RNA Modification-Related Gene Signature for Predicting Prognosis and Immunotherapeutic Efficiency of Gastric Cancer.J Oncol. 2023 Mar 8;2023:9931419. doi: 10.1155/2023/9931419. eCollection 2023. J Oncol. 2023. PMID: 36936373 Free PMC article.
-
The development of a novel signature based on the m6A RNA methylation regulator-related ceRNA network to predict prognosis and therapy response in sarcomas.Front Genet. 2022 Oct 12;13:894080. doi: 10.3389/fgene.2022.894080. eCollection 2022. Front Genet. 2022. PMID: 36313417 Free PMC article.
-
MTDeepM6A-2S: A two-stage multi-task deep learning method for predicting RNA N6-methyladenosine sites of Saccharomyces cerevisiae.Front Microbiol. 2022 Oct 5;13:999506. doi: 10.3389/fmicb.2022.999506. eCollection 2022. Front Microbiol. 2022. PMID: 36274691 Free PMC article.
-
N6-methyladenosine-associated prognostic pseudogenes contribute to predicting immunotherapy benefits and therapeutic agents in head and neck squamous cell carcinoma.Theranostics. 2022 Oct 17;12(17):7267-7288. doi: 10.7150/thno.76689. eCollection 2022. Theranostics. 2022. PMID: 36438489 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous